Dr. Medicherla leverages his 20 years of industry/biotechnology research; and 15 years of academic research experiences. Currently, he is a Chief Scientific Officer of Sirpharma Labs where he leads its Pharmacology and Toxicology activities. Recently, he was the Director of Pharmacology at Medication Inc; Associate Director of Pharmacology at Merck Research Labs; Associate Director of Pharmacology at Schering Plough; Group Leader of Pharmacology at Johnson and Johnson; and Head of the Pharmacology and Toxicology Laboratories at Calyx Therapeutics. During his research career in the industry, he has built several small molecules and protein based drug discovery programs; some of those drugs are in clinical use now. In his academic research, he studied carbohydrate and lipid metabolisms and worked closely with him, Stanford University who coined the word “metabolic syndrome”. Currently, he is an Adjunct Faculty of Environmental Toxicology, Southern University. Earlier, Fellow of Medicine, Stanford University; Research Associate at University of California-Davis; Post-doctoral Research Fellow at Temple University; and Assistant Professor at Andhra University. In his research career, he has developed a broad range of animal models in the areas of oncology, inflammatory and metabolic diseases with imaging modalities and studied pharmacology of various small molecules and large molecules in those models. He is the recipient of NIH fellowship and research grants from India. He has authored over 70 publications and holds 18 patents in the areas of diabetes and obesity.

Oncology; Inflammatory diseases; Bone diseases; Diabetes; Obesity and Hypertension.